MAPT and frontotemporal dementia: On the one hand, Flortaucipir binding has not been observed in patients with pathology-proven FTLD-tau (e.g., Pick’s disease and CBD) [189, 217], or in groups of patients with suspected FTLD-tau (e.g., patients with nfvPPA or some patients with bvFTD) [226–229].